Author Archives: Erika Erdmann

OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first prostate biopsy […]

Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer

4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announced today the results of a study for the 4Kscore® Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer […]

OPKO 4Kscore Test Receives Category I CPT Code Approval

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code for its 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer. This important event upgrades the 4Kscore Test from a Category III Administrative code to a […]

OPKO Health Refinances Bio-Reference Laboratories Credit Facility

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced today that it has successfully closed on a new five-year $175.0 million secured revolving credit facility with JPMorgan Chase. The new facility replaced Bio-Reference Laboratories’ previous $120.0 million secured revolving credit facility. “We are excited to enter into a partnership with one of the world’s premier banking institutions, JPMorgan Chase,” commented Phillip Frost, MD, Chairman & […]

OPKO Completes Acquisition of Bio-Reference Laboratories

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) and BioReference Laboratories, Inc. (NASDAQ: BRLI) today announced the completion of the acquisition of BioReference by OPKO. Shareholders of BioReference will receive 2.75 shares of OPKO common stock for each share of BioReference common stock.  “The acquisition of Bio-Reference is important for OPKO,” commented Dr. Phillip Frost, OPKO’s Chairman and Chief […]

OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced that it has entered into agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab, including the 4Kscore®Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive cancer. The cumulative contracts, with some of the largest healthcare PPO network […]

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) has been granted, effective July 1, 2015, for OPKO’s planned acquisition of Bio-Reference. This Smart News Release features multimedia. View the full release here: www.businesswire.com/news/home/20150702005579/en/ Expiration of the waiting period […]

OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first […]

OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday, June 11, 2015, to discuss the previously announced entry into a merger agreement for OPKO to acquire Bio-Reference Laboratories and to discuss Bio-Reference Laboratories’ second quarter financial results. This joint call will be in lieu of the separate earnings […]